Gypenoside XLIX loaded nanoparticles targeting therapy for renal fibrosis and its mechanism

Liu, Qixia; Chen, Xiaohui; Kan, Min; Yang, Jing; Gong, Qian; Jin, Rui; Dai, Yulong; Jin, Juan; Zang, Hongmei

doi:10.1016/j.ejphar.2021.174501

Cited by 15 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al designed a NP (diameter: 128) with a PLGA core and monolayer shell composed of a lecithin‐phosphate and mPEG‐DSPE. Following administration, a 7‐fold increase in accumulation of this NP was found in the fibrotic kidney as compared the normal kidney (Q. Liu, Chen, et al, 2021). In a different study employing a unilateral ureter obstruction (UUO) kidney model, cerium(III) NPs coated with oleylamine and DSPE‐PEG (12.7 nm) were found to accumulate at a 2‐fold higher distribution in the UUO kidney as compared with a normal kidney (M. Wang, Zeng, et al, 2022).…”

Section: Targeting Of Nanoparticles To Kidneysmentioning

confidence: 99%

A quantitative review of nanotechnology‐based therapeutics for kidney diseases

Cheng,

Ngoc Ta,

Hsia

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Kidney‐specific nanocarriers offer a targeted approach to enhance therapeutic efficacy and reduce off‐target effects in renal treatments. The nanocarriers can achieve organ or cell specificity via passive targeting and active targeting mechanisms. Passive targeting capitalizes on the unique physiological traits of the kidney, with factors like particle size, charge, shape, and material properties enhancing organ specificity. Active targeting, on the other hand, achieves renal specificity through ligand‐receptor interactions, modifying nanocarriers with molecules, peptides, or antibodies for receptor‐mediated delivery. Nanotechnology‐enabled therapy targets diseased kidney tissue by modulating podocytes and immune cells to reduce inflammation and enhance tissue repair, or by inhibiting myofibroblast differentiation to mitigate renal fibrosis. This review summarizes the current reports of the drug delivery systems that have been tested in vivo, identifies the nanocarriers that may preferentially accumulate in the kidney, and quantitatively compares the efficacy of various cargo‐carrier combinations to outline optimal strategies and future research directions.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Section: Targeting Of Nanoparticles To Kidneysmentioning

confidence: 99%

A quantitative review of nanotechnology‐based therapeutics for kidney diseases

Cheng,

Ngoc Ta,

Hsia

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Surface grafting technology is an important chemical modification method (H. Jiang et al, 2023; S. Liu, Chen, et al, 2021) based on covalent grafting via free radicals to anchor natural active compounds onto macromolecular polymer carriers, thus refining the NDDS (Sturabotti et al, 2023). For instance, introducing exogenous functional groups through this process can significantly modify and expand the characteristics of nanomaterials (Murei et al, 2021).…”

Section: Development Of Nanocarriers Based On Plant‐derived Active Co...mentioning

confidence: 99%

The development of nanocarriers for natural products

Huang,

Luo,

Tong

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Natural bioactive compounds from plants exhibit substantial pharmacological potency and therapeutic value. However, the development of most plant bioactive compounds is hindered by low solubility and instability. Conventional pharmaceutical forms, such as tablets and capsules, only partially overcome these limitations, restricting their efficacy. With the recent development of nanotechnology, nanocarriers can enhance the bioavailability, stability, and precise intracellular transport of plant bioactive compounds. Researchers are increasingly integrating nanocarrier‐based drug delivery systems (NDDS) into the development of natural plant compounds with significant success. Moreover, natural products benefit from nanotechnological enhancement and contribute to the innovation and optimization of nanocarriers via self‐assembly, grafting modifications, and biomimetic designs. This review aims to elucidate the collaborative and reciprocal advancement achieved by integrating nanocarriers with botanical products, such as bioactive compounds, polysaccharides, proteins, and extracellular vesicles. This review underscores the salient challenges in nanomedicine, encompassing long‐term safety evaluations of nanomedicine formulations, precise targeting mechanisms, biodistribution complexities, and hurdles in clinical translation. Further, this study provides new perspectives to leverage nanotechnology in promoting the development and optimization of natural plant products for nanomedical applications and guiding the progression of NDDS toward enhanced efficiency, precision, and safety.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

“…To solve the problems related to limiting the clinical application of Gyp XLIX, Liu et al . 47 obtained PLGA-Gyp XLIX nanoparticles using a poly(lactic acid)-glucoside copolymer (PLGA) loaded with Gyp XLIX. The PLGA-Gyp XLIX nanoparticles possessed a particle size of ∼120 nm and could be targeted to UUO kidneys.…”

Section: Drug Delivery Strategies For Renal Antifibrosismentioning

confidence: 99%